Trevi Therapeutics Inc’s recently made public that its Chief Commercial Officer Simon Farrell unloaded Company’s shares for reported $0.55 million on Mar 10 ’25. In the deal valued at $6.75 per share,81,313 shares were sold. As a result of this transaction, Simon Farrell now holds 76,900 shares worth roughly $0.5 million.
Then, Simon Farrell bought 81,313 shares, generating $548,880 in total proceeds.
Before that, GOOD JENNIFER L sold 4,219 shares. Trevi Therapeutics Inc shares valued at $12,784 were divested by the President & CEO at a price of $3.03 per share. As a result of the transaction, GOOD JENNIFER L now holds 213,313 shares, worth roughly $1.4 million.
Raymond James upgraded its Trevi Therapeutics Inc [TRVI] rating to a Strong buy from a an Outperform in a research note published on March 10, 2025; the price target was increased to $29 from $9. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in early March has reiterated a ‘”a Buy”‘ rating for it. H.C. Wainwright also remained covering TRVI and reiterated its “Buy” recommendation on December 12, 2024.
Price Performance Review of TRVI
On Tuesday, Trevi Therapeutics Inc [NASDAQ:TRVI] saw its stock jump 0.31% to $6.56. Over the last five days, the stock has gained 4.13%. Trevi Therapeutics Inc shares have risen nearly 59.22% since the year began. Nevertheless, the stocks have risen 109.58% over the past one year. While a 52-week high of $7.39 was reached on 03/10/25, a 52-week low of $2.30 was recorded on 01/22/25. SMA at 50 days reached $4.46, while 200 days put it at $3.39.
Levels Of Support And Resistance For TRVI Stock
The 24-hour chart illustrates a support level at 6.26, which if violated will result in even more drops to 5.96. On the upside, there is a resistance level at 7.00. A further resistance level may holdings at 7.44. The Relative Strength Index (RSI) on the 14-day chart is 76.04, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.22, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 25.78%. Stochastics %K at 76.14% indicates the stock is a holding.
How much short interest is there in Trevi Therapeutics Inc?
A steep rise in short interest was recorded in Trevi Therapeutics Inc stocks on 2025-02-28, dropping by -0.8 million shares to a total of 3.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 4.59 million shares. There was a decline of -21.13%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 30, 2024 when Raymond James began covering the stock and recommended ‘”an Outperform”‘ rating along with a $9 price target.
